Ação Exact Sciences (EXAS)
Empresa do setor de saúde. Aqui estão o preço, um resumo do negócio e o que vale a pena saber sobre Exact Sciences em outubro 2026.
Exact Sciences Corporation (EXAS) develops and commercialises non‑invasive cancer screening tests, best known for Cologuard, a stool‑based colorectal cancer screening product. Investors should know the company’s growth depends on test adoption, reimbursement from insurers and its ability to expand into other cancer diagnostics through product launches and acquisitions. Revenue has historically been driven by screening volumes, pricing and payer coverage; margins can improve as fixed costs scale but may be pressured by marketing and R&D investment. Key risks include regulatory and reimbursement uncertainty, competition from lab and diagnostic rivals, and execution challenges in commercial expansion and new test development. The stock can be volatile and is sensitive to changes in clinical data, guideline updates and policy decisions. With a market cap near $12bn, Exact Sciences may appeal to investors seeking exposure to diagnostic innovation, but it is not suitable for everyone — consider your risk tolerance and time horizon and seek independent advice before investing.
Previsão da ação Exact Sciences (EXAS)
Preço-alvo dos analistas, próximos 12 meses
$100.47
Os alvos dos analistas são opiniões, não garantias. Capital em risco. Dados de 25 mai 2026.
Fonte: o sentimento dos analistas é fornecido pela Refinitiv Ltd, líder global em dados de mercados financeiros com mais de 40 mil clientes corporativos. A Refinitiv Ltd é um terceiro independente da Nemo. Isto não é aconselhamento.
Por que você vai querer acompanhar esta ação
Screening growth potential
Colorectal screening adoption and expanded guidelines could drive volume, though uptake depends on reimbursement and patient behaviour, so outcomes can vary.
Expanding global reach
International roll‑out and partnerships may open new markets, but regulatory hurdles and local payer systems can slow progress and add uncertainty.
Pipeline and innovation
R&D and acquisitions aim to broaden cancer detection offerings; promising data can boost prospects, while negative results or delays present downside risk.
